Email: cspc@cspc.cn
News
News Center
Jul. 29
2026
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2062 INJECTION FOR THE TREATMENT OF ADULT ESSENTIAL HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE
VOLUNTARY ANNOUNCEMENT - CRB-701 (SYS6002) RECEIVES U.S. FDA CLEARANCE FOR THE REGISTRATIONAL TRIAL FOR THE SECOND-LINE TREATMENT OF OROPHARYNGEAL CANCER
Jul. 27
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF AMMOXETINE HYDROCHLORIDE ENTERIC-COATED TABLETS (HA1406) FOR THE TREATMENT OF PATIENTS WITH DEPRESSION MET
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) ACCEPTED BY THE NMPA
Jul. 24
VOLUNTARY ANNOUNCEMENT - PALIPERIDONE PALMITATE INJECTION RECEIVES MARKETING APPROVAL
Jul. 22
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6026 INJECTION FOR THE TREATMENT OF HPV TYPE 16- OR 18-RELATED CERVICAL HIGH-GRADE SQUAMOUS INTRAEPITHELI
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
